Literature DB >> 22207329

The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease.

Berenice Reed1, Imed Helal, Kim McFann, Wei Wang, Xiang-Dong Yan, Robert W Schrier.   

Abstract

BACKGROUND: The epidemic of obesity and diabetes is increasing within the USA and worldwide. We have previously shown that body mass index has increased significantly in autosomal dominant polycystic kidney disease (ADPKD) subjects seen at our center in more recent years. However, the impact of Type II diabetes in ADPKD patients has not been well studied.
METHODS: This retrospective cohort study compared clinical characteristics in 44 pre-renal transplant patients with ADPKD and diabetes and 88 age- and sex-matched non-diabetic patients with ADPKD who were seen at the University of Colorado between 1977 and 2008. The primary outcomes in this study were renal volume determined by renal ultrasonography, renal function assessed by estimated glomerular filtration rate and time to onset of end-stage renal disease or death by Kaplan-Meier analyses.
RESULTS: Diabetic patients had significantly larger kidney volumes than those with ADPKD alone [geometric mean (95% confidence interval (CI)]: 2456 (1510-3992) versus 1358 (1186-1556) cm3, P=0.02. Among those whose age at hypertension diagnosis was known, the diabetic ADPKD patients had earlier median (95% CI) age at onset of hypertension compared to those with ADPKD alone: 32.5 (28-40) versus 38 (35-42) years, P=0.04. Diabetic ADPKD patients tended to have an earlier median age of death than those with ADPKD alone.
CONCLUSIONS: Patients with ADPKD and type II diabetes have larger renal volumes, earlier age at diagnosis of hypertension and may die at a younger age compared to those patients with ADPKD alone. This study emphasizes the importance of diabetes risk management in ADPKD.

Entities:  

Mesh:

Year:  2011        PMID: 22207329      PMCID: PMC3398061          DOI: 10.1093/ndt/gfr744

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  15 in total

1.  Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kimberly K McFann; Ann M Johnson
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

Review 2.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

3.  Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality.

Authors:  R D Perrone; R Ruthazer; N C Terrin
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

4.  Renal and retinal effects of enalapril and losartan in type 1 diabetes.

Authors:  Michael Mauer; Bernard Zinman; Robert Gardiner; Samy Suissa; Alan Sinaiko; Trudy Strand; Keith Drummond; Sandra Donnelly; Paul Goodyer; Marie Claire Gubler; Ronald Klein
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

5.  Variation in age at ESRD in autosomal dominant polycystic kidney disease.

Authors:  Berenice Y Reed; Kim McFann; Mir R Bekheirnia; M Reza Bekheirnia; Niloofar Nobakhthaghighi; Niloofar Nobkhthaghighi; Amirali Masoumi; Ann M Johnson; Alireza A Shamshirsaz; Alireza Abdollah Shamshiraz; Catherine L Kelleher; Robert W Schrier
Journal:  Am J Kidney Dis       Date:  2008-02       Impact factor: 8.860

Review 6.  Causes of death in autosomal dominant polycystic kidney disease.

Authors:  G M Fick; A M Johnson; W S Hammond; P A Gabow
Journal:  J Am Soc Nephrol       Date:  1995-06       Impact factor: 10.121

7.  Autosomal dominant polycystic kidney disease reduces the risk of diabetes mellitus.

Authors:  Maria Pietrzak-Nowacka; Jacek Rózanski; Krzysztof Safranow; Karolina Kedzierska; Grazyna Dutkiewicz; Kazimierz Ciechanowski
Journal:  Arch Med Res       Date:  2006-04       Impact factor: 2.235

8.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

9.  Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.

Authors:  D Ravine; R N Gibson; R G Walker; L J Sheffield; P Kincaid-Smith; D M Danks
Journal:  Lancet       Date:  1994-04-02       Impact factor: 79.321

10.  Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects.

Authors:  O Wirta; A Pasternack; P Laippala; V Turjanmaa
Journal:  Clin Nephrol       Date:  1996-01       Impact factor: 0.975

View more
  13 in total

1.  Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage.

Authors:  Kelli M Sas; Hong Yin; Wayne R Fitzgibbon; Catalin F Baicu; Michael R Zile; Stacy L Steele; May Amria; Takamitsu Saigusa; Jason Funk; Marlene A Bunni; Gene P Siegal; Brian J Siroky; John J Bissler; P Darwin Bell
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-22

2.  The relation of anthropometric measurements and insulin resistance in patients with polycystic kidney disease.

Authors:  Bennur Esen; Emel Sağlam Gokmen; Mahmut Kaya; Burak Ozkan; Ahmet Engin Atay
Journal:  J Transl Int Med       Date:  2016-09-23

Review 3.  Analytic Considerations for Repeated Measures of eGFR in Cohort Studies of CKD.

Authors:  Haochang Shou; Jesse Y Hsu; Dawei Xie; Wei Yang; Jason Roy; Amanda H Anderson; J Richard Landis; Harold I Feldman; Afshin Parsa; Christopher Jepson
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-27       Impact factor: 8.237

4.  Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.

Authors:  Jacob A Torres; Samantha L Kruger; Caroline Broderick; Tselmeg Amarlkhagva; Shagun Agrawal; John R Dodam; Michal Mrug; Leslie A Lyons; Thomas Weimbs
Journal:  Cell Metab       Date:  2019-10-17       Impact factor: 27.287

Review 5.  Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction.

Authors:  Baris Afsar; Rengin Elsurer Afsar; Atalay Demiray; Sevval Altay; Hakan Korkmaz; Abdulmecit Yildiz; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Clin Kidney J       Date:  2022-01-31

Review 6.  Is autosomal dominant polycystic kidney disease an early sweet disease?

Authors:  Angélique Dachy; Jean-Paul Decuypere; Rudi Vennekens; François Jouret; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2022-01-05       Impact factor: 3.651

7.  Glucose promotes secretion-dependent renal cyst growth.

Authors:  Andre Kraus; Gunnar Schley; Karl Kunzelmann; Rainer Schreiber; Dorien J M Peters; Ruth Stadler; Kai-Uwe Eckardt; Bjoern Buchholz
Journal:  J Mol Med (Berl)       Date:  2015-09-03       Impact factor: 4.599

Review 8.  Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.

Authors:  Kristen L Nowak; Katharina Hopp
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-21       Impact factor: 8.237

9.  Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats.

Authors:  Sarika Kapoor; Daniel Rodriguez; Meliana Riwanto; Ilka Edenhofer; Stephan Segerer; Katharyn Mitchell; Rudolf P Wüthrich
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

10.  Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease.

Authors:  Miyeun Han; Hayne Cho Park; Hyunsuk Kim; Hyung Ah Jo; Hyuk Huh; Joon Young Jang; Ah-Young Kang; Seung Hyup Kim; Hae Il Cheong; Duk-Hee Kang; Jaeseok Yang; Kook-Hwan Oh; Young-Hwan Hwang; Curie Ahn
Journal:  BMC Nephrol       Date:  2014-04-16       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.